Literature DB >> 27542070

Reexamining the Threshold for Reexcision of Histologically Transected Dysplastic Nevi.

Nathaniel H Fleming1, Barbara M Egbert2, Jinah Kim3, Susan M Swetter1.   

Abstract

Importance: Controversy persists regarding the appropriate management of incompletely excised, biopsy-proven, mild and moderate dysplastic nevi (DN). Objective: To determine long-term risk of associated melanoma in biopsied mild or moderate DN with positive histologic margins that were clinically observed vs reexcised with negative margins. Design, Setting, and Participants: Retrospective cohort study of mixed referral and community patients from an academic pigmented lesion clinic and dermatology clinics of the affiliated Veteran Affairs medical center with biopsy-confirmed DN with positive histologic margins diagnosed from May 15, 1991, to July 8, 2015, and followed up through May 30, 2016. A consecutive sample of 1473 histologically confirmed DN was identified using surgical pathology databases at the study sites; 590 cases in 498 patients met eligibility criteria. Main Outcomes and Measures: The primary outcome was the proportion of biopsied DN that progressed to histologically confirmed invasive or in situ melanoma. Secondary outcomes included local nevus recurrence and development of primary melanoma at other anatomic sites.
Results: The 498 patients had a mean (range) age of 57.6 (14-93) years and 90% were male. Among 590 positive-margin DN, 191 were reexcised and 399 clinically observed without further surgery; 170 reexcised and 304 observed DN had available follow-up data, with mean (SD) follow-up of 5.5 (4.6) years. Cases in the observation group were more likely to demonstrate nevus recurrence than those that were reexcised (3.3% vs 0%; P = .02). Six of 304 (2.0%) observed DN subsequently developed melanoma at the same site, compared with 1 of 170 (0.06%) that were reexcised (P = .43). Five of 6 observed patients who developed melanoma initially underwent partial biopsy with grossly positive margins; 1 melanoma in situ evolved from an excisionally biopsied moderately dysplastic nevus 5 years later. Only 1 case of thin invasive melanoma (≤1 mm) was observed, and no deaths from melanoma arising from biopsy-proven DN occurred through the latest dermatology follow-up. New primary melanoma developed at other sites in 9.9% of excised and 9.4% of resected DN. Conclusions and Relevance: In cases of mild and moderate DN with microscopically positive margins and no concerning clinical residual lesion, observation, rather than reexcision, was a reasonable management option. Partial biopsies of pigmented lesions suspicious for melanoma may lead to delayed melanoma diagnosis and should be discouraged.

Entities:  

Mesh:

Year:  2016        PMID: 27542070     DOI: 10.1001/jamadermatol.2016.2869

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  7 in total

1.  Diagnostic Accuracy of Virtual Pathology vs Traditional Microscopy in a Large Dermatopathology Study.

Authors:  Michael N Kent; Thomas G Olsen; Theresa A Feeser; Katherine C Tesno; John C Moad; Michael P Conroy; Mary Jo Kendrick; Sean R Stephenson; Michael R Murchland; Ayesha U Khan; Elizabeth A Peacock; Alexa Brumfiel; Michael A Bottomley
Journal:  JAMA Dermatol       Date:  2017-12-01       Impact factor: 10.282

2.  Fast raster-scan optoacoustic mesoscopy enables assessment of human melanoma microvasculature in vivo.

Authors:  Hailong He; Christine Schönmann; Mathias Schwarz; Benedikt Hindelang; Andrei Berezhnoi; Susanne Annette Steimle-Grauer; Ulf Darsow; Juan Aguirre; Vasilis Ntziachristos
Journal:  Nat Commun       Date:  2022-05-19       Impact factor: 17.694

3.  Risk of Subsequent Cutaneous Melanoma in Moderately Dysplastic Nevi Excisionally Biopsied but With Positive Histologic Margins.

Authors:  Caroline C Kim; Elizabeth G Berry; Michael A Marchetti; Susan M Swetter; Geoffrey Lim; Douglas Grossman; Clara Curiel-Lewandrowski; Emily Y Chu; Michael E Ming; Kathleen Zhu; Meera Brahmbhatt; Vijay Balakrishnan; Michael J Davis; Zachary Wolner; Nathaniel Fleming; Laura K Ferris; John Nguyen; Oleksandr Trofymenko; Yuan Liu; Suephy C Chen
Journal:  JAMA Dermatol       Date:  2018-12-01       Impact factor: 10.282

Review 4.  Using Implementation Science to Optimize the Uptake of Evidence-Based Medicine into Dermatology Practice.

Authors:  Sepideh Ashrafzadeh; Joshua P Metlay; Niteesh K Choudhry; Karen M Emmons; Maryam M Asgari
Journal:  J Invest Dermatol       Date:  2019-12-18       Impact factor: 8.551

5.  Economic Analysis of a Noninvasive Molecular Pathologic Assay for Pigmented Skin Lesions.

Authors:  John Hornberger; Daniel M Siegel
Journal:  JAMA Dermatol       Date:  2018-09-01       Impact factor: 10.282

6.  Incomplete Excisions of Melanocytic Lesions: Rates and Risk Factors.

Authors:  Sofia Berglund; Eva Johansson Backman; Zahra Baldawi; Linda Horn; Rebecca Arbin Borsiin; Michelle Marjanovic; Thea Christoffersson; Martin Gillstedt; John Paoli
Journal:  Acta Derm Venereol       Date:  2021-03-23       Impact factor: 3.875

7.  Pathologists' agreement on treatment suggestions for melanocytic skin lesions.

Authors:  Mustufa A Jafry; Sue Peacock; Andrea C Radick; Hannah L Shucard; Lisa M Reisch; Michael W Piepkorn; Stevan R Knezevich; Martin A Weinstock; Raymond L Barnhill; David E Elder; Kathleen F Kerr; Joann G Elmore
Journal:  J Am Acad Dermatol       Date:  2019-12-17       Impact factor: 11.527

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.